Atypical Hemolytic Uremic Syndrome Clinical Trials in London
3 recruitingLondon, United Kingdom
Showing 1–3 of 3 trials
Recruiting
Phase 3
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals50 enrolled31 locationsNCT05935215
Recruiting
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
PregnancyParoxysmal Nocturnal Hemoglobinuria, PNHUltomiris-exposed Pregnant/ Postpartum+3 more
Alexion Pharmaceuticals, Inc.75 enrolled7 locationsNCT06312644
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
Atypical Hemolytic Uremic Syndrome
Alexion Pharmaceuticals, Inc.3,000 enrolled141 locationsNCT01522183